Minerva Neurosciences, Inc: Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
WALTHAM, Mass., Aug. 22, 2022(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the
United States Helen Shik Remy Luthringer Frederick Ahlholm Minerva Neurosciences Exchange Commission
Source: finanznachrichten.de